Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGIS CORPRGS · Entity 8808 | Director · President and CEO | November 22, 2024 | November 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGIS CORP
Report date November 22, 2024 · Filed November 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,584 |
Reported balance
After 2024-11-22 transaction · row 1
1 source rowRow 1 · 2024-11-22 · Grant · Acquired 16,500 · Balance 19,584 F1: The award vests as to 1/3 of the shares on the first, second, and third anniversaries of the grant date, subject to the Reporting Person's continued employment with the Issuer through such anniversaries and the other terms and conditions of the grant agreements. |
Filing footnotes · ownership attribution and instrument terms
F1: The award vests as to 1/3 of the shares on the first, second, and third anniversaries of the grant date, subject to the Reporting Person's continued employment with the Issuer through such anniversaries and the other terms and conditions of the grant agreements.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2024 Filed Nov 26, 2024 22:23 UTC | REGIS CORP RGS · Entity 8808 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027765 · form4-11262024_101111.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,584 F1 · shares: The award vests as to 1/3 of the shares on the first, second, and third anniversaries of the grant date, subject to the Reporting Person's continued employment with the Issuer through such anniversaries and the other terms and conditions of the grant agreements. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 23:58 UTC | REGIS CORP RGS · Entity 8808 | Tax withholdingCommon Stock | 339 | $23.37 | $7,922.43 |
DisclosureSEC source: 0001415889-24-026379 · form4-11072024_111134.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,292 F1 · balance_after: Previous number of shares beneficially owned, 72,662, adjusted for 1-for-20 reverse stock split, to 3,631. This also corrects the share amount disposed for taxes on February 8, 2024, that was adjusted for the reverse split but subtracted from the unadjusted. Read SEC document |
| November 05, 2024 Filed Nov 19, 2024 23:27 UTC Amendment | REGIS CORP RGS · Entity 8808 | Tax withholdingCommon Stock | 547 | $23.37 | $12,783.39 |
DisclosureSEC source: 0001415889-24-027260 · form4a-11192024_111111.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,084 F1 · shares: The reporting person's Form 4 filed on November 7, 2024 inadvertently understated the shares withheld by 208 shares. F2 · balance_after: Previous number of shares beneficially owned, 72,662, adjusted for 1-for-20 reverse stock split, to 3,631. This also corrects the share amount disposed for taxes on February 8, 2024, that was adjusted for the reverse split but subtracted from the unadjusted. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 15:57 UTC | REGIS CORP RGS · Entity 8808 | Tax withholdingCommon Stock | 211 | $12.35 | $2,605.85 |
DisclosureSEC source: 0000716643-24-000010 · wk-form4_1707494234.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,671 Read SEC document |
| November 06, 2023 Filed Nov 8, 2023 21:31 UTC | REGIS CORP RGS · Entity 8808 | Tax withholdingCommon Stock | 3,648 | $0.53 | $1,933.44 |
DisclosureSEC source: 0000716643-23-000048 · wk-form4_1699479083.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,882 Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 20:40 UTC | REGIS CORP RGS · Entity 8808 | Tax withholdingCommon Stock | 2,837 | $1.26 | $3,574.62 |
DisclosureSEC source: 0000716643-22-000090 · wf-form4_166802639614336.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,530 Read SEC document |
| May 05, 2022 Filed May 9, 2022 23:38 UTC | REGIS CORP RGS · Entity 8808 | GrantStock Options · Derivative | 875,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000716643-22-000026 · wf-form4_165213949417953.xml · derivative · entry 1 Doctor Matthew · CIK 0001844838 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 Underlying: Common Stock · 875,000 shares Expires 2032-05-05 F1 · derivative.exercise_date: The award vests at the rate of 20% on the first anniversary of the grant date, 20% on the second anniversary of the grant date and 60% on the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer through such anniversaries and other terms of the grant agreements. Read SEC document |
| February 08, 2022 Filed Mar 2, 2022 22:17 UTC | REGIS CORP RGS · Entity 8808 | Tax withholdingCommon Stock | 4,343 | $1.65 | $7,165.95 |
DisclosureSEC source: 0000716643-22-000020 · wf-form4_164625942099879.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,367 Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:33 UTC | REGIS CORP RGS · Entity 8808 | GrantStock Appreciation Rights · Derivative | 112,500 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0000716643-21-000084 · wf-form4_163649355954851.xml · derivative · entry 4 Doctor Matthew · CIK 0001844838 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-11-05 F3 · derivative.exercise_date: The award vests as to 20% of the shares on the first anniversary of the grant date, 20% of the shares on the second anniversary of the grant date and 60% of the shares on the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer through such anniversaries and the other terms and conditions of the grant agreements. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:33 UTC | REGIS CORP RGS · Entity 8808 | GrantStock Options · Derivative | 112,500 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0000716643-21-000084 · wf-form4_163649355954851.xml · derivative · entry 3 Doctor Matthew · CIK 0001844838 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-11-05 F3 · derivative.exercise_date: The award vests as to 20% of the shares on the first anniversary of the grant date, 20% of the shares on the second anniversary of the grant date and 60% of the shares on the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer through such anniversaries and the other terms and conditions of the grant agreements. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:33 UTC | REGIS CORP RGS · Entity 8808 | GrantCommon Stock | 34,758 | $0.00 | $0.00 |
DisclosureSEC source: 0000716643-21-000084 · wf-form4_163649355954851.xml · nonDerivative · entry 2 Doctor Matthew · CIK 0001844838 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,124 F2 · shares: The Reporting Person was awarded a grant of 34,758 restricted stock units (RSUs) pursuant to the SPMP. The RSUs will vest 20% on the first anniversary of the grant date, 20% on the second anniversary of the grant date, and 60% on the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer through such anniversaries and the other terms and conditions of the grant agreement. Each RSU represents the contingent right to receive one share of RGS common stock upon vesting. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:33 UTC | REGIS CORP RGS · Entity 8808 | GrantCommon Stock | 12,234 | $2.76 | $33,765.84 |
DisclosureSEC source: 0000716643-21-000084 · wf-form4_163649355954851.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,366 F1 · shares: The Reporting Person elected to participate in the Issuer's Stock Purchase and Matching RSU Program (SPMP). The Reporting Person purchased 12,234 shares of RGS common stock under the SPMP. Read SEC document |
| November 05, 2021 Filed Nov 16, 2021 21:25 UTC Amendment | REGIS CORP RGS · Entity 8808 | GrantCommon Stock | 46,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-010175 · edgar.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,710 F1 · shares: The Reporting Person was awarded a grant of 46,344 restricted stock units (RSUs) pursuant to the SPMP. The RSUs will vest 20% on the first anniversary of the grant date, 20% on the second anniversary of the grant date, and 60% on the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer through such anniversaries and the other terms and conditions of the grant agreement. Each RSU represents the contingent right to receive one share of RGS common stock upon vesting. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 18:19 UTC | REGIS CORP RGS · Entity 8808 | GrantCommon Stock | 28,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000716643-21-000031 · wf-form4_161289474320002.xml · nonDerivative · entry 1 Doctor Matthew · CIK 0001844838 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,132 F1 · shares: The Reporting Person was awarded a grant of 28,382 restricted stock units (RSUs). One-half of the RSUs vest on the first anniversary of the grant date and the remaining half vests on the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer through such anniversary and the other terms and conditions of the grant agreement. Each RSU represents the contingent right to receive one share of RGS common stock upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.